Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Article
Medicare to provide limited relief for biologic payment
Amgen has gotten Medicare to pay for limited amounts of Enbrel, the $1,000-a-month rheumatoid-arthritis drug. The coverage, tucked in the new Medicare law that covers drugs for seniors, includes some expensive biotech drugs that patients can inject themselves, such as Enbrel and a rival, Abbott Laboratories' Humira.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Related Videos
Related Content
Published: March 8th 2025 | Updated: March 8th 2025
